Inherent Biosciences

Executive Summary

Inherent Biosciences is a privately held biotechnology company leveraging epigenetics and AI to develop diagnostic tools for complex diseases, with an initial focus on male infertility. Founded in 2015 in Salt Lake City, Utah, the company aims to remove guesswork from diagnosis by analyzing epigenetic markers. Its first commercial product addresses the significant unmet need in male infertility, where current diagnostic methods are often inadequate. By combining AI-driven analysis with epigenetic insights, Inherent offers a novel approach that could improve accuracy and personalization of treatment. The company operates in the growing reproductive health diagnostics market, with potential to expand into other disease areas. While specific funding details and stage are not disclosed, Inherent's focus on a clear clinical need and innovative technology positions it as a promising player in precision diagnostics.

Upcoming Catalysts (preview)

• Q2 2027Launch of first commercial product for male infertility70% success
• Q1 2027Publication of clinical validation study80% success
• Q3 2026Partnership with major fertility clinic network60% success